A low-grade litigation between drug purchasers and big pharma is breaking out. The implications for orthopedic and spine surgery include drug availability (hospital, clinic or ASC), cost and access for patients pre- and post-surgery.
The litigation, specifically MDL 2724, alleges that Sandoz Inc. and other generic drug manufacturers conspired to fix the prices of generic drugs.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
